HIRO-CAPITAL
7.2.2020 01:03:10 CET | Business Wire | Press release
Fresh from a legendary launch at CES 2020, NURVV – the biomechanics innovator using British science to disrupt the global wearables industry – is today announcing it has closed its first venture funding round, led by Hiro Capital.
Hiro Capital – the new Sports technology, Games and Esports VC Fund led by Inspired Entertainment co-founder Luke Alvarez, Games Workshop co-founder Ian Livingstone CBE and Cherry Freeman, co-founder of LoveCrafts - has invested $9m in NURVV’s husband and wife team of serial entrepreneurs Jason and Ulrica Roberts.
The money will be used to bring NURVV’s debut product, NURVV Run, to a global market; to fund further research and development into its patented biomechanics sensor technologies and to support the founders in achieving their aim of helping 10 million runners to improve their technique.
NURVV Run was unveiled at this year’s Pepcom during the Consumer Electronics Show in Las Vegas to great acclaim, featuring on multiple Best of CES lists from the likes of Wired, CNET and Gear Patrol. NURVV Run also won US Today’s Editor’s Choice award which handpicks winners that strike a balance in innovation, technology, design, and value.
Tested by hundreds of athletes, universities and leading institutions including SATRA Technology and the National Physical Laboratory over the past three years, the system uses 32 high-precision sensors fitted inside lightweight insoles to accurately capture data from the feet at 1,000 times per second, per sensor.
This data, which includes unique running metrics such as cadence, step length, footstrike, pronation and balance, is fed into the NURVV Run coaching app to show a complete picture of the wearer’s running technique. It uses advanced biomechanics to deliver simple, actionable insights as well as personalised coaching that gives guidance on how to improve before, during and after each run.
Its in-run, real-time coaching creates gamified speed and technique workouts to help wearers run at a target pace, to a chosen finish time or beat a personal record with responsive audio, visual and haptic feedback. Real-time prompts detailing step length, cadence and pace on critical splits also help keep runners on track to hit their goals.
This not only helps runners improve their technique and pace, it can help reduce injury via a Running Health score.
The Running Health score helps reduce injury by analysing each runner’s training load, pronation, cadence and balance – to identify problem areas before they become serious. Runners can also optimise their training with recommendations on the right distance to run to achieve their optimal training zone and avoid overtraining.
The NURVV Run insoles are compatible with all running shoes, are rain and mud proof and come with a five-hour active battery life. The system ships with two GPS trackers and access to the free NURVV Run Coaching app. Runners can connect the system to IOS, Apple Watch, Android and to ANT+ (Garmin) wearables.
“Runners are already able to collect a huge amount of data about each and every run they do. However, most of what they capture is historic, inaccurate and provides few insights on how to be a better runner,” said Jason Roberts, founder and CEO of NURVV. “NURVV Run revolutionises how people run by accurately capturing the metrics that matter most, directly from the point of action at the foot, before using live coaching to help them improve in a simple, easy-to-understand way.”
“From the very beginning of this journey we kept coming back to the same question: ‘Why is running measured from the wrist, when most of the important metrics happen at the feet?’,” added co-founder Ulrica Roberts. “Driven by the idea we could revolutionise running by putting core biomechanical principles at the heart of our solution, we sought out the expertise to make it happen.”
“Combining our cutting-edge wearable technology, in-house biomechanics expertise, and ongoing dialogue with the running community, NURVV Run is the most comprehensive tool for runners who crave more detailed information on their performance and technique,” said Dr. Grant Trewartha, head of biomechanics at NURVV.
Luke Alvarez, Managing Partner of Hiro, said: “Hiro is delighted to be investing in NURVV as our Fund’s fourth deal and our first Sports tech investment. NURVV’s success comes from putting the athlete’s body at the heart of everything they do. NURVV is based on fundamental patented sensor technologies combined with deep biomechanics and data science that have revolutionary potential across sports, gaming, VR/AR and wellness. Jason and Ulrica are extraordinary entrepreneurs and we are excited to be working with them and their team to take NURVV to the next level.”
NURVV Run has been tested during 22 million steps of durability testing and 30,000 miles covered on the road.
ENDS
About NURVV
NURVV is on a mission to provide runners with the power to understand what their bodies are truly capable of and find their true potential. We pioneer the latest advances in technology and biomechanics. We capture running from the point of action and analyze run-data using advanced biomechanics to deliver actionable insights and live in-run coaching. We are dedicated to all runners who want to improve their running and aim to change 10 million lives with a new way of knowing by 2025. https://www.nurvv.com/
About Hiro Capital
Hiro Capital is a Luxembourg / London technology Venture Capital fund which invests in European and UK innovators in Games, Esports and Digital Sports. Hiro Capital generally invests at the post-seed Series A and B stages. We invest both in front-end Content creators in Games, Esports and Digital Sports and in deep tech sector-specific applications of Cloud, Mobile, Streaming, Big Data, AI, Wearables, AR and VR technologies.
We back experienced entrepreneurial teams, building innovative technologies and content with a strongly differentiated proposition and with the scaling opportunity to become very large.
We are Games, Esports and Sports investors who are also Games, Esports and Sports entrepreneurs. Our core belief is that Games, Esports and Digital Sports will be a central pillar of Entertainment, Economic and Social Life in the mid 21st century. We invest in the innovators who are building that future. https://hiro.capital/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005997/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
